Blood
Articles in this Issue
Solvitur ambulando
Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis
Abstract Dexamethasone is a key component of induction for newly diagnosed multiple myeloma (NDMM), despite common toxicities, including hyperglycemia and insomnia. In the randomized...
Down with dex!
Parvovirus B19-induced autoimmune hemolytic anemia in hereditary elliptocytosis
How I treat Philadelphia chromosome–like acute lymphoblastic leukemia in children, adolescents, and young adults
Abstract Philadelphia chromosome–like acute lymphoblastic leukemia (Ph-like ALL) represents a high-risk B-lineage ALL subtype characterized by adverse clinical features and poor rela...
How I treat ETP-ALL in children
Abstract Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is a unique subtype of immature T-cell ALL that was initially associated with a dramatically inferior prognosis...
How I treat infant acute lymphoblastic leukemia
Abstract Infant acute lymphoblastic leukemia (ALL) is an aggressive malignancy that has historically been associated with a very poor prognosis. Despite large cooperative internation...
How I treat older patients with Ph/BCR-ABL–negative acute lymphoblastic leukemia
Abstract Despite advancements in new treatments, management of older patients with acute lymphoblastic leukemia (ALL) remains an unmet medical need. With increasing age, patients wit...
Introduction to a How I Treat series on acute lymphoblastic leukemia
Edited by Associate Editor Hervé Dombret, this How I Treat series highlights the clinical approach to high-risk subgroups of acute lymphoblastic leukemia (ALL). These include adult Philadelphia chromo...
How I treat adult Ph+ ALL
Abstract The Philadelphia (Ph) chromosome is one of the few genetic aberrations in which a casualty has been proven and, as such, represents a success in the history of medicine. Thi...
Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria
Abstract Iptacopan, a novel oral factor B inhibitor, recently obtained US Food and Drug Administration approval for treating paroxysmal nocturnal hemoglobinuria, a rare blood disorde...
How I treat postimmunotherapy relapsed B-ALL
Abstract Despite significant advancements in single-antigen targeted therapies for B-cell acute lymphoblastic leukemia (B-ALL), nonresponse and relapse persist as major challenges. A...
An erythroid-specific lentiviral vector improves anemia and iron metabolism in a new model of XLSA
Abstract X-linked sideroblastic anemia (XLSA) is a congenital anemia caused by mutations in ALAS2, a gene responsible for heme synthesis. Treatments are limited to pyridoxine supplem...
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma
Abstract Ciltacabtagene autoleucel (cilta-cel) was approved in 2022 for patients with relapsed/refractory multiple myeloma (RRMM). We report outcomes with cilta-cel in the standard-o...
XLSA breakthrough: gene therapy potential
Vitamin C deprivation puts stem cells to sleep
Ascorbate deficiency increases quiescence and self-renewal in hematopoietic stem cells and multipotent progenitors
Abstract Ascorbate (vitamin C) limits hematopoietic stem cell (HSC) function and suppresses leukemia development, partly by promoting the function of the Tet2 tumor suppressor. In hu...